Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;59(12):3698-3713.
doi: 10.1111/trf.15546. Epub 2019 Nov 5.

Pre-clinical Development of a Cryopreservable Megakaryocytic Cell Product Capable of Sustained Platelet Production in Mice


Pre-clinical Development of a Cryopreservable Megakaryocytic Cell Product Capable of Sustained Platelet Production in Mice

Ami Patel et al. Transfusion. .


Background: Platelet (PLT) transfusions are the most effective treatments for patients with thrombocytopenia. The growing demand for PLT transfusion products is compounded by a limited supply due to dependency on volunteer donors, a short shelf-life, risk of contaminating pathogens, and alloimmunization. This study provides preclinical evidence that a third-party, cryopreservable source of PLT-generating cells has the potential to complement presently available PLT transfusion products.

Study design and methods: CD34+ hematopoietic stem/progenitor cells derived from umbilical cord blood (UCB) units were used in a simple and efficient culture system to generate a cell product consisting of megakaryocytes (MKs) at different stages of development. The cultures thus generated were evaluated ex vivo and in vivo before and after cryopreservation.

Results: We generated a megakaryocytic cell product that can be cryopreserved without altering its phenotypical and functional capabilities. The infusion of such a product, either fresh or cryopreserved, into immune-deficient mice led to production of functional human PLTs which were observed within a week after infusion and persisted for 8 weeks, orders of magnitude longer than that observed after the infusion of traditional PLT transfusion products. The sustained human PLT engraftment was accompanied by a robust presence of human cells in the bone marrow (BM), spleen, and lungs of recipient mice.

Conclusion: This is a proof-of-principle study demonstrating the creation of a cryopreservable megakaryocytic cell product which releases functional PLTs in vivo. Clinical development of such a product is currently being pursued for the treatment of thrombocytopenia in patients with hematological malignancies.

Similar articles

See all similar articles



    1. Fletcher CH, DomBourian MG, Millward PA. Platelet transfusion for patients with cancer. Cancer Control 2015;22:47-51.
    1. Kumar A, Mhaskar R, Grossman BJ, et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion 2015;55:1116-27 quiz 1115.
    1. Whitaker BI, Hinkins S. The 2011 national blood collection and utilization survey report. Washington, DC: The United States Department of Health and Human Services; 2011.
    1. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142:348-60.
    1. Woolthuis CM, Park CY. Hematopoietic stem/progenitor cell commitment to the megakaryocyte lineage. Blood 2016;127:1242-8.

Publication types

LinkOut - more resources